PsoriasisPoster 35Long-term safety and efficacy of roflumilast cream 0.3% in adult patients with chronic plaque psoriasis: results from a 52-week...
PsoriasisPoster 36Roflumilast cream, a once-daily, potent phosphodiesterase-4 inhibitor, in chronic plaque psoriasis patients: Efficacy and safety...
PsoriasisPoster 37Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis Who Had Inadequate...
PsoriasisPoster 38Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, Versus Placebo in Scalp, Nail, and Palmoplantar Psoriasis...
PsoriasisPoster 39Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO Program
PsoriasisPoster 40Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3...
PsoriasisPoster 41Efficacy and Safety of Calcipotriene Topical Foam 0.005% in Maintenance Treatment of Moderate Plaque-Type Psoriasis After Combination...
PsoriasisPoster 42Patient Preference for Calcipotriene/Betamethasone Fixed Combination Cream vs Foam: A Pilot Study
PsoriasisPoster 43Effectiveness, safety, and quality of life from a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis
PsoriasisPoster 44Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five...
PsoriasisPoster 45Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment...
PsoriasisPoster 46Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients...
PsoriasisPoster 47Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials...
PsoriasisPoster 48Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials
PsoriasisPoster 49Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients...